

## Special Issue

# Lymphoma Biology, Pathology and Stem Cells

### Message from the Guest Editor

We welcome research papers or review articles from novel perspectives to focus on the following topics reflecting the new area in the diagnosis and treatment of lymphomas:

- Lymphoma pathology: new entities, phenotypic studies of T/NK or B-cell lymphomas, WHO vs. ICC, changing the paradigms in the molecular classification of lymphomas;
- Lymphoma biology: molecular studies on the regulation of cell cycle activation, driver mutations in initiation metabolic control of lymphomagenesis, progression and transformation of lymphomas;
- Basic and translational studies of lymphoid cells and the immune cell microenvironment;
- Lymphoma stem cells, cancer metabolism, cooperative genetic and epigenetic interactions in normal and transformed lymphoma cells;
- Tumor immunology: searching for tumor antigens as targets for vaccine strategies, HSCT, new strategy improving the CAR-T and immunotherapy in patient selection and monitoring the prognosis.

### Guest Editor

Prof. Dr. Mingyi Chen

Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

### Deadline for manuscript submissions

31 December 2025



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/181862](https://mdpi.com/si/181862)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)